Description
Ribociclib is a type of cancer growth blocker. It targets the proteins cyclin dependant kinase 4 and cyclin dependant 6 (CDK 4 and CDK 6) on breast cancer cells. CDK 4 and CDK 6 are proteins that stimulate cancer cells to divide and grow. Ribociclib works by blocking these proteins.
Ribociclib was approved by the US Food and Drug Administration (FDA) in March 2017, by the European Medicines Agency (EMA) in August 2017, and for use in the National Health Service (NHS) by National Institute for Health and Care Excellence (NICE) in February 2021.